Very little information to the contrary of success. Forgive my naivety here, but I actually don’t know what you mean here. From what I’ve seen, RAC has been extremely communicative and transparent via the appropriate official channels/ASX announcements. I don’t know what more information ‘contrary of success’ you’d like. Daniel has explicitly acknowledged current risks for investing in RAC/bisantrene’s commercial & clinical success, what more would you like?
RAC - Charts & Price Action, page-22550
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.65 | $179.8K | 108.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1437 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 3313 | 1 |
View Market Depth
| Last trade - 15.58pm 03/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |